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Abstract
Concomitantly with the increase in the prevalences 
of overweight/obesity, nonalcoholic fatty liver disease 
(NAFLD) has worldwide become the main cause of 
chronic liver disease in both adults and children. 
Patients with fatty liver display features of metabolic 
syndrome (MetS), like insulin resistance (IR), glucose 
intolerance, hypertension and dyslipidemia. Recently, 
epidemiological studies have linked obesity, MetS, 
and NAFLD to decreased bone mineral density and 
osteoporosis, highlighting an intricate interplay among 
bone, adipose tissue, and liver. Osteoprotegerin (OPG), 
an important symbol of the receptor activator of nuclear 
factor-B ligand/receptor activator of nuclear factor 
kappa B/OPG system activation, typically considered 
for its role in bone metabolism, may also play critical 
roles in the initiation and perpetuation of obesity-
related comorbidities. Clinical data have indicated that 
OPG concentrations are associated with hypertension, 
left ventricular hypertrophy, vascular calcification, 
endothelial dysfunction, and severity of liver damage 
in chronic hepatitis C. Nonetheless, the relationship 
between circulating OPG and IR as a key feature of 
MetS as well as between OPG and NAFLD remains 
uncertain. Thus, the aims of the present review are to 
provide the existent knowledge on these associations 
and to discuss briefly the underlying mechanisms linking 
OPG and NAFLD.
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Core tip: Recently, epidemiological studies have linked 
obesity, metabolic syndrome, and nonalcoholic fatty 
liver disease (NAFLD) to decreased bone mineral 
density and osteoporosis, highlighting an intricate 
interplay among bone, adipose tissue, and liver. 
Osteoprotegerin (OPG), an important symbol of the 
receptor activator of nuclear factor-B ligand/receptor 
activator of nuclear factor kappa B/OPG axis activation, 
has recently been suggested to have critical roles 
in the initiation and perpetuation of obesity-related 
comorbidities including NAFLD. The available studies 
have reported either positive or negative associations 
between OPG and NAFLD. Thus, more research is 
needed to clarify its role in this liver disease.
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INTRODUCTION
Concomitantly with the increase in the prevalences 
of overweight/obesity, nonalcoholic fatty liver disease 
(NAFLD) has worldwide become the main cause of 
chronic liver disease in both adults and children[1,2]. 
NAFLD implies accumulation of lipids within hepatocytes, 
with a spectrum ranging from simple steatosis to 
steatohepatitis (NASH), progressive to cirrhosis[3-5]. 
Although patients with NAFLD have a high risk of 
mortality from liver complications, the primary cause 
of mortality in such patients is cardiovascular disease 
(CVD)[6]. Indeed, NAFLD may be considered in adults as 
well as in children a multisystem disease affecting several 
extra-hepatic organs and involving a range of extra-
hepatic chronic diseases, in particular type 2 diabetes, 
CVD, and chronic renal disease[7-11]. These diseases 
have the same underlying pathophysiological features 
associated with metabolic syndrome (MetS), including 
insulin resistance (IR), chronic systemic inflammation 
and hyperlipidemia. Recently, epidemiological studies 
have linked obesity, MetS, and NAFLD to decreased bone 
mineral density (BMD) and osteoporosis, highlighting 
an intricate interplay among bone, adipose tissue, and 
liver[12-14]. With regard to this, the association between 
NAFLD and decreased BMD has been also reported in the 
pediatric obese population[15,16]. 
Osteoprotegerin (OPG), an important symbol of the 
receptor activator of nuclear factor-B ligand (RANKL)/
receptor activator of nuclear factor kappa B (RANK)/
OPG axis activation, has recently been highlighted as 
an important factor of the biochemical mechanisms 
underlying the association between MetS and CVD[17-20]. 
Tumor necrosis factor (TNF) superfamily molecules, 
namely, RANKL, its receptor (RANK), and its soluble 
(decoy) receptor, OPG, mediate interactions (RANKL-OPG 
axis) that exert multiple actions on bone metabolism, 
endocrine functions, and the immune system[21-23]. 
The RANKL-OPG axis is typically considered for its role 
in bone metabolism, but proinflammatory cytokines 
[e.g., interleukin (IL)-1b, IL-6, and TNF-α] that are 
regulated by the RANKL-OPG axis in mediating bone 
resorption in osteoporosis, may also play critical roles 
in the initiation and perpetuation of obesity-related 
comorbidities[21-23]. There is arising evidence that RANKL/
RANK/OPG system participate in the pathogenesis of 
atherosclerosis and CVD by expanding the detrimental 
actions of inflammation and multiple risk factors including 
dyslipidemia, endothelial dysfunction, type 2 diabetes, 
and high blood pressure[20]. 
Clinical data have displayed that circulating OPG 
concentrations are associated with hypertension and left 
ventricular hypertrophy in the general population, with 
vascular calcification and altered endothelial function in 
subjects with and without diabetes, and with severity of 
liver damage in patients with chronic hepatitis C[22-25]. 
Moreover, epidemiological studies have shown that OPG 
concentrations may predict morbidity and mortality from 
CVD[26]. Nonetheless, still the association of circulating 
OPG with IR as a key feature of MetS as well as of OPG 
with NAFLD remains uncertain. Thus, the aims of the 
present review are to provide the existent knowledge 
on these associations and to discuss briefly the possible 
underlying mechanisms linking OPG and NAFLD. We 
searched in MEDLINE and EMBASE databases utilizing 
the words “OPG”, “RANKL”, “RANK”, “IR”, “MetS”, and 
“NAFLD” individually and in combination to recruit all 
published articles from 1990 to 2018.
OPG/RANK/RANKL SYSTEM
OPG, first recognized in 1997, is a cytokine belonging 
to the superfamily of TNF receptor[27-30]. It has been 
termed OPG for its protective role in bone. The OPG gene 
discovered and cloned in 1998 is a single -copy gene 
localized on chromosome 8 (8q24) consisting of five 
exons over 29 kilobases[31]. Fom a biochemical aspect, 
OPG is a glycoprotein with a primary structure of 401 
aminoacids and a molecular weight of 60 kilodaltons. OPG 
has seven structural domains, which actuate its biological 
functions in specific manners[32]. The amino terminal 
domains one to four, containing plenty of cysteine, impart 
osteclastogenesis inhibitory characteristics. Domains five 
and six at the carboxy terminal end include apoptosis-
mediating death domain homologous regions. Domain 
seven encloses a heparin-binding region along with a free 
cysteine residue required for disulfide bond formation 
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and dimerization. In fact, further to its monomeric 
structure, OPG may be completed at the cys-400 residue 
in the heparin binding domain to constitute a disulphide-
linked dimer[32]. Before being secreted as monomeric and 
dimeric forms, the twenty-one aminoacid’s signal peptide 
of OPG is split from the N-terminal achieving a 380 
aminoacid’s mature OPG protein. Therefore, as long as 
the OPG monomer is biologically active, OPG homodimer 
molecule is more active and its production is necessary 
to generate complete biological activity in vitro and in 
vivo. This is because the homodimer form possesses 
higher affinity for the RANKL ectodomain than the OPG 
monomer. RANKL and TNF-related apoptosis-inducing 
ligand (TRAIL) bind to OPG with similar affinities[32]. 
OPG is highly expressed in various organs and 
tissues including osteoblasts, lungs, cardiac tissue, 
renal tissue, hepatic tissue, spleen, thymus, prostate, 
ovary, small intestine, thyroid, lymphnodes, trachea, 
adrenal gland, testis, and bone marrow, endothelial 
cells and vascular smooth cells, while it is encountered 
at very low levels in brain, placenta, and skeletal 
muscle[23,26,33]. OPG has also been discovered by means 
of immunohistochemistry in atherosclerotic plaques 
of aortas and coronary arteries. Furthermore, OPG 
expression has recently been demonstrated in human 
adipose tissue[34].
RANK, an additional member of the TNF receptor 
superfamily, is expressed on the surface of hematopoietic 
precursor cells and mediates signaling that activates 
osteoclastogenesis[35]. Its ligand RANKL is typically 
expressed on osteoblast/stromal cell surfaces. RANKL 
is also encountered in stimulated T-lymphocytes, lymph 
nodes, thymus, mammary gland, lungs, spleen and bone 
marrow. It is a transmembrane protein, however, in the 
blood is also present a soluble form (sRANKL). sRANKL 
seems to derive from cleavage of membrane RANKL or 
to be produced by T-lymphocytes. Membrane-bound 
RANKL or sRANKL binds to RANK through interaction 
with specific molecules such as TNF receptor-associated 
factor (TRAF) proteins. The most important role of TRAFs 
in RANK-RANKL signaling is the stimulation of NF-kBs as 
well as mitogen-activated protein kinases and interferon-
regulatory molecules. TRAF proteins may also take part 
to chronic inflammatory state and infection[36]. 
ROLE OF OPG/RANK/RANKL SYSTEM IN 
BONE AND OTHER TISSUES
The wide variety of cells and tissues in major organ 
systems such as the skeletal, vascular, and immune 
systems as well as other systems producing OPG, 
RANKL, and RANK support their role in the function 
of these organs (Figure 1). Typically, the OPG/RANK/
RANKL axis regulates remodeling of bone as well as 
differentiation and activation of osteoclasts, and thus, 
the crucial equilibrium between formation and resorption 
of bone. RANKL binds to RANK on osteoprogenitor cells 
and controls osteoclastogenesis and bone resorption. 
OPG acting as a soluble decoy receptor, negatively 
regulates this interaction and competes with RANK, 
preventing RANKL-RANK interactions. 
While OPG is expressed in the vessels of healthy 
mice, RANK and RANKL are not detected in the arteries 
of healthy adult mice. In contrast, RANKL and RANK 
have been discovered in the calcified arteries of OPG-/- 
mice and RANK expression occurred simultaneously with 
the appearance of multinuclear osteoclast-like cells[37]. 
These findings suggest that vascular OPG protects 
against RANK/RANKL induced osteoclast formation. In 
humans, RANKL and RANK are often undetected in the 
non-diseased vessel, while OPG is expressed in normal 
arteries. However, early as well as advanced human 
atherosclerotic lesions of carotid arteries and abdominal 
aortas manifest both RANKL and OPG immunoreactivity 
and mRNA expression[38-40]. 
Immune cells express OPG, RANKL, and RANK and 
these are believed to regulate inflammatory and immune 
responses[41-43]. Binding of RANKL to RANK augments 
dentritic cells’ survival, enhances the immunostimulatory 
capacity of dentritic cells, and modulates activated T-cells. 
In particular, RANKL/RANK signaling in the immune 
system controls the development of thymocyte-mediated 
medulla, and the development of self-tolerance in T 
cells as well as the number of regulatory T cells (Treg). 
RANKL also regulates the production of proinflammatory 
cytokines in macrophages[41]. An important function of 
OPG in the immune system is related to the cytotoxic 
ligand TRAIL, a potent activator of apoptosis. Binding of 
OPG to TRAIL inhibits cell apoptosis[44]. 
Yet, OPG, RANKL, and RANK have been demonstrated 
to be expressed in normal brain of rodents. Notably, in 
normal brain, RANKL/RANK signaling has been related to 
fever and body temperature control. The stimulation of 
RANKL/RANK signaling obtained by the deletion of OPG 
or the administration of RANKL has been demonstrated 
to prevent the exacerbation of infart volume as well as 
cerebral edema through the inhibition of the production 
of pro-inflammatory cytokines[45]. 
The multiple actions of OPG/RANKL/RANK axis, 
including modulation of cell survival, mineralization and 
inflammation suggest a potential role as mediator of 
metabolic complications including insulin resistance, 
type 2 diabetes, MetS and NAFLD.
CLINICAL STUDIES
Insulin resistance
NAFLD is strictly associated with IR, which is also a main 
determinant in the pathogenesis of type 2 diabetes and 
MetS. Even if investigators agree that IR is determined 
by alterations in intracellular insulin signaling, various 
causes have been suggested to explain by what means 
such insulin signaling alterations originate in NAFLD. 
Inflammation, activation of endoplasmic reticulum 
stress pathways, and deposit of lipids in hepatocytes 
have all been proposed to determine IR in NAFLD[46,47]. 
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in prediabetic patients than in control individuals. 
There was a positive relationship between sRANKL 
and OPG. Yet, sRANKL was positively associated with 
body mass index (BMI), HOMA-IR, and inflammatory 
markers such as high-sensitivity CRP. Duan et al[55] 
demonstrated that circulating OPG concentrations were 
increased in Chinese postmenopausal women with 
diabetes and prediabetes. Moreover, serum OPG levels 
showed significant correlation with IR. Mashavi et al[56] 
showed that OPG values were significantly increased 
in postmenopausal women affected by osteoporosis 
and impaired glucose metabolism (including impaired 
glucose tolerance and type 2 diabetes) than women 
with normal glucose tolerance. OPG concentrations 
were independently associated with IR as evaluated 
by HOMA-IR. Recently, Daniele et al[57] found that high 
OPG concentrations were correlated with increased 
endogenous glucose production (primarily reflecting 
liver glucose production) and hepatic IR in individuals 
with impaired glucose regulation, supporting the possi-
bility that OPG could have a role in glucose homeos-
tasis derangement that usually precede overt type 2 
diabetes.
There have also been some studies demonstrating a 
negative relationship between OPG and IR, though they 
were predominantly based on healthy populations. In a 
healthy population (exhibiting normal glucose tolerance 
and exercise stress tests, thus excluding hyperglycemia 
and ischemic heart disease, respectively), Ashley et al[58] 
found that OPG correlated inversely with HOMA-IR, and 
suggested that high IR in healthy subjects is associated 
with low levels of circulating OPG. In a subsequent 
Numerous studies have reported on the association 
between OPG and IR with contrastant results[48-62]. 
In a cohort of 106 subjects with obesity, including 
eighteen with type 2 diabetes, Gannage-Yared et al[48] 
demonstrated a positive relationship between OPG and 
IR as evaluated by the homeostasis model assessment 
for IR (HOMA-IR). In a cross-sectional study, Yaturu et al[49] 
demonstrated that OPG was significantly associated 
with insulin levels and IR as well as with C-reactive 
protein (CRP) and TNF-α in patients affected by type 
2 diabetes, most likely reflecting the proinflammatory 
state in this population. Pepene et al[50] reported a 
positive association of OPG with HOMA-IR in a cohort of 
women with polycystic ovary syndrome. Akinci et al[51] 
found that women with a history of gestational diabetes 
mellitus developing MetS showed increased OPG values 
compared to women who did not fulfill MetS criteria. 
Yet, these authors showed that OPG concentrations 
were associated with markers of IR, with carotid 
intima-media thickness (IMT) and with subclinical 
inflammation. Suliburska et al[52] found that HOMA-
IR values and OPG values were significantly increased 
in obese adolescents than in the control group. A 
significant positive correlation between OPG and IR was 
found. In a large population of individuals with normal 
glucose tolerance (n = 599), with impaired glucose 
tolerance (n = 730) and with newly diagnosed diabetes 
(n = 327), respectively, Niu et al[53] demonstrated that 
elevated circulating OPG levels were independently 
related to impaired glucose regulation and a higher risk 
of microalbuminuria. Bilgir et al[54] found that circulating 
OPG and sRANKL values were significantly increased 
Physiological Pathophysiological
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Figure 1  Role of osteoprotegerin/ receptor activator of nuclear factor-B ligand/receptor activator of nuclear factor kappa B axis in physiological and 
pathophysiological conditions.
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study, these authors showed that OPG was higher in 
patients with abnormal glucose tolerance compared to 
normoglycemic healthy subjects[59]. Nonethless, OPG 
did not correlate with the severity of IR as evaluated 
by HOMA-IR either on univariate or multiple linear 
regression, suggesting that OPG elevation in these 
individuals may be due to other factors. In agreement 
with these findings, Ugur-Altun and colleagues[60,61] 
in two separate studies - the former involving obese 
patients without diabetes vs lean healthy subjects, 
the latter healthy young women - found a negative 
relationship between OPG and IR. Ayina Ayina et al[62] 
demonstrated that HOMA-IR was inversely associated 
with OPG values in women with obesity, meaning that 
elevated OPG concentrations may be expression of high 
insulin sensitivity. 
The heterogeneity of the results of the studies on 
the association between OPG and IR might reflect 
differences in the population included in terms of gender, 
age, ethnic background, and, importantly, in terms 
of metabolic-associated diseases. Indeed, a positive 
relationship has been found in studies that involved 
individuals with high levels of IR, such as those affected 
by type 2 diabetes and a previous history of gestational 
diabetes, while a negative relationship in those that 
involved healthy subjects. It should be acknowledged 
that elevated circulating OPG has emerged as a strong, 
independent predictor of CVD[63,64]. In particular, plasma 
OPG is considered a marker of vascular calcifications[65], 
a feature often seen in patients with impaired glucose 
homeostasis[66] and recently shown to involve insulin 
actions[67]. OPG concentrations in patients affected 
by obesity and type 2 diabetes may thus reflect the 
presence of CVD.
Metabolic syndrome
Scant and contrastant literature is available on the 
association between OPG and MetS. Initial studies found 
no correlation between OPG and MetS[68,69]. In particular, 
in a cohort of elderly Lebanese men, Gannage-Yared 
et al[68] found no significant difference in OPG con-
centrations between individuals with and without MetS. 
Similar findings were reported by Nabipour et al[69] in a 
population-based sample of postmenopausal women. 
In subsequent studies, however, an association between 
OPG and MetS has been reported. In individuals with 
peripheral artery disease, circulating concentrations of 
OPG were raised in obese patients with MetS[70]. Akinci 
et al[51] found that women with a history of gestational 
diabetes mellitus developing the MetS showed increased 
OPG levels than women who did not fulfill the MetS 
criteria. These findings were previously reported by the 
same authors in a sample of 128 women with previous 
gestational diabetes and 67 age-matched controls. OPG 
values were associated with obesity, IR, and carotid 
IMT[71]. 
Recently, Pérez de Ciriza et al[72] demonstrated 
that patients with MetS had significantly elevated OPG 
concentrations than those without the syndrome. Of 
note, OPG values significantly and positively correlated 
with the number of cardiovascular risk factors. In 
addition, OPG expression in adipose tissue was endorsed, 
and MetS patients expressed elevated OPG mRNA 
values compared to those without. Bernardi et al[73] 
demonstrated that circulating OPG was higher in patients 
with MetS compared to controls. In high-fat diet fed 
C57BL6 mice, they also found that OPG was elevated, 
and that OPG administration promoted systemic and 
adipose tissue proinflammatory changes resembling 
those observed in HDF fed mice. Finally, in patients with 
type 2 diabetes, Tavintharan et al[74] found OPG to be a 
significant predictor of MetS also after adjustment for 
age, sex, ethnic origin, glucose levels, and microvascular 
complications. 
The variation of the results of the studies on the 
association between MetS and OPG may be in part 
explained by differences in the population included 
in terms of gender, age and associated diseases, and 
importantly, in diagnostic criteria utilized.
NAFLD
There are few studies on the relationship between 
OPG and NAFLD, with either positive or negative 
associations having being described[75-80] (Table 1). In 
a cross-sectional study, Yilmaz et al[75] first reported 
that OPG levels were significantly decreased in patients 
with definite and borderline NASH than in subjects 
with simple liver steatosis. The authors also found a 
negative relationship between OPG and HOMA-IR, and 
between OPG and serum transaminases values. Thus, 
low OPG concentration in subjects affected by NAFLD 
may reflect the effects of IR, as well as the occurrence 
of severe liver necroinflammation. Yang et al[76] tested 
the accuracy of non-invasive biological markers for 
identification of NASH, including OPG, in 179 patients 
with biopsy-proven NAFLD (training group) and 91 age- 
and sex-matched healthy controls. Further 63 subjects 
with NAFLD were separately included as validation 
group. Serum levels of OPG decreased progressively 
from controls to patients with NAFLD but without 
NASH, and reached the lowest levels in patients with 
NASH. Sensitivity and specificity of OPG for assessing 
NASH were 81.30% and 74.60%, respectively. In 
a case-control study involving 746 patients affected 
by type 2 diabetes (of whom 367 with ultrasound-
diagnosed NAFLD), Niu et al[77] demonstrated that the 
OPG concentrations were significantly decreased in 
patients with NAFLD compared to patients without liver 
involvement. The subjects in the lowest OPG quartile 
were at higher risk for NAFLD. Finally, Erol et al[78] 
evaluated the association of OPG concentrations with 
obesity, IR, and NAFLD in children and adolescents. OPG 
concentrations in the youth with obesity were signifi-
cantly decreased than in controls. Among obese youths, 
those with high fasting insulin and high HOMA-IR values 
displayed significantly lower OPG values. Patients with 
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hepatic steatosis had lower OPG concentrations than 
those without liver involvement, although they did not 
reach statistical significance. In contrast, Ayaz et al[79] 
demostrated that patients with NAFLD diagnosed via 
ultrasonography had OPG levels significantly higher 
compared to controls. Monseu et al[80] determined the 
association between OPG and visceral adipose tissue and 
liver fat content as measured by magnetic resonance 
imaging, as well as other markers of the MetS in dys-
metabolic adults. OPG levels were positively correlated 
with visceral fat liver and liver fat content, as well as liver 
markers such as alanine aminotransferase and HOMA-IR 
index. 
Some points must be considered when interpreting 
the results of the few aforementioned studies. First, half 
of them have included a small sample size. Second, the 
clinical heterogeneity of patients’ population enrolled 
in the studies. Third, methodologic heterogeneity in 
defining the reference standard. In fact, liver disease 
was differently evaluated, with the majority of the 
studies utilizing ultrasonography that is known to be 
unable to assess severity of liver disease such as NASH. 
BIOLOGICAL ROLE OF OPG IN NAFLD
OPG acting like a decoy receptor for TRAIL and RANKL 
neutralizes their biological actions. Of note, TRAIL is a 
relevant inductor of apoptosis in hepatocyte cells[81]. 
Because enhanced hepatocyte apoptosis has a key role 
in the progression of liver disease, that is from simple 
steatosis to NASH[82], it is tempting to suppose that the 
decrease in circulating concentrations of OPG in NAFLD, 
observed in the majority of the studies, might be 
responsible for alterations in the mechanisms protecting 
against hepatocyte apoptosis. Notably, accumulation of 
OPG is closely related to reduced apoptosis in several 
cell types[81,83]. These findings may imply that OPG exert 
a common defensive effect on the pathophysiologic 
derangements responsible for NAFLD through at 
least two different mechanisms: The first mechanism 
involves IR, while the second is based on protection of 
hepatocytes from cell death by apoptosis. Nonethless, 
the exact mechanisms responsible for the decrease of 
OPG in subjects with NAFLD and NASH need additional 
studies. 
ANIMAL DATA
The development of transgenic technologies in mice has 
led to advances in knowledge of the role of OPG/RANKL/
RANK system in bone metabolism and cardiometabolic 
functions. Concerning cardiometabolic disorders, Hao 
et al[84] showed that OPG-/- mice exhibited a significant 
increase in systolic blood pressure since early stages 
of life, and that this rise was in parallel with the 
osteoporotic change in these mice. OPG-/- mice also 
Table 1  Studies assessing the association between osteoprotegerin and nonalcoholic fatty liver disease
Ref. Study design Population Findings
Yilmaz et al[75], 2010 Cross-sectional study 56 adult patients with histological-proven definite 
NASH; 26 with borderline NASH; 17 with simple 
fatty liver; and 58 healthy controls without evidence 
of liver disease (normal results on liver function tests 
and normal liver ultrasound).
OPG levels were significantly decreased in patients 
with definite NASH and borderline NASH than 
in controls. No significant differences were found 
between patients with simple fatty liver and controls.
Ayaz et al[79], 2014 Case-control study 60 adult patients with ultrasound-proven NAFLD 
and 30 control subjects.
OPG levels were significantly increased in patients 
with NAFLD compared to control subjects.
Yang et al[76], 2015 Cross-sectional study 179 patients with biopsy-proven NAFLD (training 
group) and 91 age- and gender-matched healthy 
subjects. 63 other NAFLD patients were separately 
collected as validation group.
Serum levels of OPG decreased in a stepwise fashion 
in controls, non-NASH NAFLD patients and NASH 
patients.
Monseu et al[80], 2016 Cross-sectional study 314 adult subjects with at least one criterion for 
metabolic syndrome.
OPG levels were positively associated with both 
liver markers (such as alanine aminotransferase, 
gamma-glutamyl transferase and ferritin levels) and 
increased liver fat content as assessed by magnetic 
resonance imaging.
Niu et al[77], 2016 Case-control study 746 adult patients with type 2 diabetes, of whom 367 
with ultrasound-proven NAFLD.
OPG levels were significantly decreased in patients 
with NAFLD compared to those without NAFLD.
Participants in the lowest OPG quartile had a 
significantly increased risk for NAFLD (OR = 3.49, 
95%CI: 1.86-6.94).
Erol et al[78], 2016 Cross-sectional study 107 children with obesity of whom 62 had 
ultrasound-proven NAFLD and 37 control subjects.
OPG levels in the obese group were significantly 
lower than in controls. Among obese youths, those 
with high fasting insulin and high HOMA-IR values 
had significantly lower OPG levels. Patients with 
hepatic steatosis had lower OPG concentrations than 
those without liver involvement, although they did 
not reach statistical significance.
NASH: Non-alcoholic steatohepatitis; OPG: Osteoprotegerin; NAFLD: Nonalcoholic fatty liver disease; HOMA-IR: Homeostasis model assessment for 
insulin resistance.
Pacifico L et al . OPG/RANKL/RANK axis in NAFLD
2079 May 21, 2018|Volume 24|Issue 19|WJG|www.wjgnet.com
presented a higher heart weight/body weight ratio 
than age-matched wild-type mice, indicating that OPG 
plays an important role in the preservation of cardiac 
structure. Kiechl et al[85] developed hepatocyte-specific 
RANK knockout (RANKLKO) mice and compared them 
with wild-type mice. While RANKWT mice experienced 
insulin resistance after 4 wk of a high-fat diet (NFD), 
RANKLKO mice did not. A very recent study demonstrated 
that mice lacking β-catenin in osteoblasts exhibit during 
the postnatal period reduced bone mass, increased 
glucose level, reduced insulin production, reduced 
fat accumulation and increased energy expenditure. 
OPG overexpression normalized not only the reduced 
bone mass but also the reduced fat accumulation and 
increased energy expenditure[86].
CONCLUSION
Contention still exists on the exact role of OPG/RANKL/
RANK system in IR and NAFLD. The available studies 
have reported either positive or negative associations 
between OPG and IR as well as between OPG and 
NAFLD. As previously outlined, possible explanations 
of the discordant results may be related to differences 
in the study population in terms of gender, age, ethnic 
background, and, importantly, in terms of cardiometa-
bolic-associated diseases. Interestingly, OPG seems 
to have a dichotomous role in humans, as suggested 
in CVD. In healthy subjects, the proatherogenic and 
antiatherogenic effects are being held in a fine balance, 
while in the presence of persistent risk factors the pro-
atherogenic pathway becomes predominant. Moreover, 
there are differences between human and animal 
studies. Observational studies in human subjects show 
that circulating OPG concentrations are associated 
positively with severity and progression of coronary 
artery disease, atherosclerosis, and vascular calcification 
whereas animal studies support a protective role for 
OPG[87]. Future studies are necessary to clarify the role 
of OPG in NAFLD.
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